Nucleai
PrivateLast Round
Series B
Extension
Apr 3, 2024
Total Funding Raised
$58.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nucleai operates in Healthcare & Life Sciences and is based in Chicago, Illinois. Its latest recorded funding round was a Series B Extension round in April 2024.
Nucleai is a biotechnology company that offers a spatial biology software platform designed to enhance precision medicine through advanced artificial intelligence and machine learning technologies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleai Comparables
Compare Nucleai with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aignostics | 87% | |
| Panakeia | 84% | |
| Visiopharm | 82% |
For institutional investors. Book with your work email.
Nucleai Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 3, 2024 | ||||
| Series B | Mar 22, 2022 | ||||
| Series A | Jul 7, 2020 | ||||
| Seed | Mar 5, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nucleai Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B Extension, Series B |
| Fosun RZ Capital | Series B Extension, Series B |
| Grove Ventures | Series A, Series B Extension, Series B, Seed |
| M Ventures | Series B Extension |
| Vvc Advisors | Series B |
| Fosun International Capital | Series B |
| Vertex Ventures Israel | Series A, Series B Extension, Series B, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 192% MoM, reaching 5.6K.
- Apr 15, 2026
Integrated spatial proteomics solution for drug development.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withAug 18, 2026
Nucleai, Inc. and Gilead Sciences, Inc. are engaged in an ongoing translational research collaboration supporting global ADC clinical development through AI-driven analysis of H&E and IHC whole-slide images across multiple oncology studies, announced in Israel on Aug 11th '26.
For institutional investors. Book with your work email.
Nucleai Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nucleai's valuation, stock price, and market status.
Is Nucleai a public or private company?
Nucleai is a private company.
What is the current stock price of Nucleai?
Nucleai is a private company, so its shares have no public market price. Caplight tracks Nucleai's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nucleai worth (valuation)?
Valuation information for Nucleai is not publicly available.
Can I buy Nucleai stock?
Nucleai shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nucleai's last funding round?
Nucleai's most recent funding round was Series B Extension on April 3, 2024.
Who are the main investors in Nucleai?
Key investors in Nucleai include S32, Grove Ventures, M Ventures, Vertex Ventures Israel, Sanofi Ventures.
Will Nucleai IPO soon?
No public IPO plans have been announced for Nucleai.
How can I track Nucleai secondary market activity?
Caplight tracks bids, offers, and trades in Nucleai's shares on secondary markets.